
    
      The study includes an 8-week antihyperglycemic agent (AHA) wash-off period* (which includes a
      2-week single-blind placebo run-in period) followed by a 24-week double-blind treatment
      period. All participants will receive open-label acarbose at a minimum dose of 50 mg three
      times daily (t.i.d.) during the run-in and treatment periods.

      *: Wash-off only applicable to patients who were on acarbose and another AHA.
    
  